AI Article Synopsis

  • Alzheimer disease (AD) is influenced by genetic factors, particularly loss-of-function (LoF) variants of the SORL1 gene, which increase the risk of developing AD; assessing how these variants affect individuals as they age is crucial for genetic counseling and preventive measures.* -
  • The researchers developed a method to estimate the age-related risk of SORL1-LoF variants by analyzing data from a large study and an extended family dataset, considering the additional risk factor of the APOE-ε4 genotype.* -
  • Results indicated that by age 70, 100% of APOE-ε4ε4 carriers with SORL1-LoF variants are expected to develop AD, highlighting the need to consider

Article Abstract

Background: Alzheimer disease (AD) is a common complex disorder with a high genetic component. Loss-of-function (LoF) SORL1 variants are one of the strongest AD genetic risk factors. Estimating their age-related penetrance is essential before putative use for genetic counseling or preventive trials. However, relative rarity and co-occurrence with the main AD risk factor, APOE-ε4, make such estimations difficult.

Methods: We proposed to estimate the age-related penetrance of SORL1-LoF variants through a survival framework by estimating the conditional instantaneous risk combining (i) a baseline for non-carriers of SORL1-LoF variants, stratified by APOE-ε4, derived from the Rotterdam study (N = 12,255), and (ii) an age-dependent proportional hazard effect for SORL1-LoF variants estimated from 27 extended pedigrees (including 307 relatives ≥ 40 years old, 45 of them having genotyping information) recruited from the French reference center for young Alzheimer patients. We embedded this model into an expectation-maximization algorithm to accommodate for missing genotypes. To correct for ascertainment bias, proband phenotypes were omitted. Then, we assessed if our penetrance curves were concordant with age distributions of APOE-ε4-stratified SORL1-LoF variant carriers detected among sequencing data of 13,007 cases and 10,182 controls from European and American case-control study consortia.

Results: SORL1-LoF variants penetrance curves reached 100% (95% confidence interval [99-100%]) by age 70 among APOE-ε4ε4 carriers only, compared with 56% [40-72%] and 37% [26-51%] in ε4 heterozygous carriers and ε4 non-carriers, respectively. These estimates were fully consistent with observed age distributions of SORL1-LoF variant carriers in case-control study data.

Conclusions: We conclude that SORL1-LoF variants should be interpreted in light of APOE genotypes for future clinical applications.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238165PMC
http://dx.doi.org/10.1186/s13073-022-01070-6DOI Listing

Publication Analysis

Top Keywords

sorl1-lof variants
20
variant carriers
12
alzheimer disease
8
apoe genotypes
8
age-related penetrance
8
penetrance curves
8
age distributions
8
sorl1-lof variant
8
case-control study
8
sorl1-lof
7

Similar Publications

Penetrance estimation of Alzheimer disease in SORL1 loss-of-function variant carriers using a family-based strategy and stratification by APOE genotypes.

Genome Med

June 2022

Normandie Université, UNIROUEN, Inserm U1245, CHU Rouen, Department of Genetics and CNRMAJ, FHU-G4 Génomique, 22 boulevard Gambetta - CS 76183, Rouen, F-76000, France.

Article Synopsis
  • Alzheimer disease (AD) is influenced by genetic factors, particularly loss-of-function (LoF) variants of the SORL1 gene, which increase the risk of developing AD; assessing how these variants affect individuals as they age is crucial for genetic counseling and preventive measures.* -
  • The researchers developed a method to estimate the age-related risk of SORL1-LoF variants by analyzing data from a large study and an extended family dataset, considering the additional risk factor of the APOE-ε4 genotype.* -
  • Results indicated that by age 70, 100% of APOE-ε4ε4 carriers with SORL1-LoF variants are expected to develop AD, highlighting the need to consider
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!